GENE ONLINE|News &
Takeda Inks $3.6 Billion Deal with Poseida to Advance Non-Viral Gene Therapies and Overcome Safety Issues
Takeda seems to have embarked on a deal-making binge in the past few days. Just last week, the Japanese pharma giant signed a billion-dollar strategic partnership with Selecta Biosciences to develop targeted gene therapies for lysosomal storage disorders. Yesterday, it emulated that with another massive deal!
On October 11th, Takeda announced a $3.6 billion gene therapy pact with San Diego-based Poseida Therapeutics. The exclusive license agreement aims to utilize Poseida's proprietary technologies for the research and development of up to eight gene therapies.
Speaking to GeneOnline, Eric Ostertag, CEO of Poseida Therapeutics, said both companies are philosophically very aligned in terms of patient care and in trying to get innovative treatments to patients with unmet medical needs, primarily pediatric patients.
On October 11th, Takeda announced a $3.6 billion gene therapy pact with San Diego-based Poseida Therapeutics. The exclusive license agreement aims to utilize Poseida's proprietary technologies for the research and development of up to eight gene therapies.
Speaking to GeneOnline, Eric Ostertag, CEO of Poseida Therapeutics, said both companies are philosophically very aligned in terms of patient care and in trying to get innovative treatments to patients with unmet medical needs, primarily pediatric patients.
GO Prime with only $1.49 now
LATEST
EVENT
